232 related articles for article (PubMed ID: 35093147)
1. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
3. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy.
Schwab ME; Shao S; Zhang L; Lianoglou B; Belter L; Jarecki J; Schroth M; Sumner CJ; MacKenzie T
Prenat Diagn; 2022 Oct; 42(11):1409-1419. PubMed ID: 36029101
[TBL] [Abstract][Full Text] [Related]
4. Treating lysosomal storage disorders: What have we learnt?
Lachmann RH
J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
[TBL] [Abstract][Full Text] [Related]
5. Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects.
Herzeg A; Borges B; Lianoglou BR; Gonzalez-Velez J; Canepa E; Munar D; Young SP; Bali D; Gelb MH; Chakraborty P; Kishnani PS; Harmatz P; Cohen JL; MacKenzie TC
Prenat Diagn; 2023 Dec; 43(13):1638-1649. PubMed ID: 37955580
[TBL] [Abstract][Full Text] [Related]
6. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
Li M
Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
[TBL] [Abstract][Full Text] [Related]
7. Advances in therapies for neurological lysosomal storage disorders.
Ellison S; Parker H; Bigger B
J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180
[TBL] [Abstract][Full Text] [Related]
8. Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.
Baik AD; Calafati P; Zhang X; Aaron NA; Mehra A; Moller-Tank S; Miloscio L; Praggastis M; Giovannone N; Pan C; Tang Y; Bridges S; Mujica A; Barbounis P; Yanolatos J; Gale N; Li N; Kyratsous CA; Schoenherr CJ; Murphy AJ; Economides AN; Cygnar KD
Mol Ther; 2021 Dec; 29(12):3512-3524. PubMed ID: 34400331
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal storage diseases: Stem cell-based cell- and gene-therapy.
Kim SU
Cell Transplant; 2014 May; ():. PubMed ID: 24853878
[TBL] [Abstract][Full Text] [Related]
10. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study.
Ditters IAM; van der Beek NAME; Brusse E; van der Ploeg AT; van den Hout JMP; Huidekoper HH
Orphanet J Rare Dis; 2023 May; 18(1):108. PubMed ID: 37158969
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease).
Rohman PJ; Scott E; Richfield L; Ramaswami U; Hughes DA
J Obstet Gynaecol Res; 2016 Oct; 42(10):1263-1271. PubMed ID: 27384519
[TBL] [Abstract][Full Text] [Related]
12. Cardiac involvement in Lysosomal Storage Diseases.
Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
Rohrbach M; Clarke JT
Drugs; 2007; 67(18):2697-716. PubMed ID: 18062719
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for lysosomal storage diseases (LSDs) in large animal models.
Haskins M
ILAR J; 2009; 50(2):112-21. PubMed ID: 19293456
[TBL] [Abstract][Full Text] [Related]
15. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families.
Freedman R; Sahhar M; Curnow L; Lee J; Peters H
J Genet Couns; 2013 Aug; 22(4):517-32. PubMed ID: 23536258
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lysosomal storage diseases: recent patents and future strategies.
Ortolano S; Viéitez I; Navarro C; Spuch C
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models.
Ellinwood NM; Vite CH; Haskins ME
J Gene Med; 2004 May; 6(5):481-506. PubMed ID: 15133760
[TBL] [Abstract][Full Text] [Related]
18. The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy.
Heinrich R; Claus F; Schoenfelder T
Mol Genet Metab Rep; 2023 Jun; 35():100971. PubMed ID: 37065272
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy for lysosomal storage diseases.
Ohashi T
Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
